Literature DB >> 12417379

APOE genotype in cerebrovascular disease and vascular dementia.

A Frank1, E Díez-Tejedor, M J Bullido, F Valdivieso, P Barreiro.   

Abstract

BACKGROUND: The fact that the allele epsilon 4 of the Apolipoprotein E (APOE) gene could act like a risk factor not only in late-onset familial and sporadic Alzheimer's disease (AD) but also in cerebrovascular disease (CVD) and vascular dementia (VaD) is still controversial.
METHODS: In order to study if epsilon 4 allele is overrepresented not only in AD but also in CVD and VaD, APOE genotyping was undertaken in a series of 247 patients: 26 cases with VaD, 41 cases with CVD but without cognitive impairment (CVD-C), 83 cases with AD and 97 aged-matched "healthy controls" (HC).
RESULTS: Percentages of subjects bearing one or two copies of the epsilon 4 allele was much higher in AD patients (54%) than in either CVD-C (29%) (p<0.05), VaD (15%) (p<0.001) or HC (13%) (p<0.001).
CONCLUSIONS: These results strengthen the hypothesis that involves the APOE epsilon 4 allele as a predisposing factor for AD, but not for CVD or VaD.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12417379     DOI: 10.1016/s0022-510x(02)00286-1

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  11 in total

Review 1.  Innate immune responses to HIV infection in the central nervous system.

Authors:  Rebeca Geffin; Micheline McCarthy
Journal:  Immunol Res       Date:  2013-12       Impact factor: 2.829

2.  Apolipoprotein E epsilon4 offers protection against age-related macular degeneration.

Authors:  Duncan A Friedman; Walter J Lukiw; James M Hill
Journal:  Med Hypotheses       Date:  2006-12-04       Impact factor: 1.538

3.  Structural differences between apoE3 and apoE4 may be useful in developing therapeutic agents for Alzheimer's disease.

Authors:  Carl Frieden; Kanchan Garai
Journal:  Proc Natl Acad Sci U S A       Date:  2012-05-21       Impact factor: 11.205

4.  APOE ε2 and ε4 influence the susceptibility for Alzheimer's disease but not other dementias.

Authors:  Carlo Lovati; Daniela Galimberti; Diego Albani; Pierluigi Bertora; Eliana Venturelli; Giuliana Cislaghi; Ilaria Guidi; Chiara Fenoglio; Francesca Cortini; Francesca Clerici; Dario Finazzi; Gianluigi Forloni; Elio Scarpini; Claudio Mariani
Journal:  Int J Mol Epidemiol Genet       Date:  2010-04-05

Review 5.  Poststroke dementia in the elderly.

Authors:  Marie-Anne Mackowiak-Cordoliani; Stéphanie Bombois; Armelle Memin; Hilde Hénon; Florence Pasquier
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

Review 6.  Apolipoprotein E alleles can contribute to the pathogenesis of numerous clinical conditions including HSV-1 corneal disease.

Authors:  James M Hill; Partha S Bhattacharjee; Donna M Neumann
Journal:  Exp Eye Res       Date:  2006-09-26       Impact factor: 3.467

7.  Associations between APOE polymorphisms and seven diseases with cognitive impairment including Alzheimer's disease, frontotemporal dementia, and dementia with Lewy bodies in southeast China.

Authors:  Ke-Liang Chen; Yi-Min Sun; Yan Zhou; Qian-Hua Zhao; Ding Ding; Qi-Hao Guo
Journal:  Psychiatr Genet       Date:  2016-06       Impact factor: 2.458

8.  Apolipoprotein E4 Suppresses Neuronal-Specific Gene Expression in Maturing Neuronal Progenitor Cells Exposed to HIV.

Authors:  Rebeca Geffin; Ricardo Martinez; Alicia de Las Pozas; Biju Issac; Micheline McCarthy
Journal:  J Neuroimmune Pharmacol       Date:  2017-03-20       Impact factor: 4.147

9.  Apolipoprotein E isoform dependently affects Tat-mediated HIV-1 LTR transactivation.

Authors:  Nabab Khan; Gaurav Datta; Jonathan D Geiger; Xuesong Chen
Journal:  J Neuroinflammation       Date:  2018-03-20       Impact factor: 8.322

10.  Association of apolipoprotein E genotype with outcome in hospitalized ischemic stroke patients.

Authors:  Yajing Zhang; Shuling Liu; Wei Yue; Zhihong Shi; Yalin Guan; Mingzi Li; Yong Ji; Xin Li
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.